Alex L. Zhang was 13 years old when he published a video game that went viral. More than 100,000 people bought the game for ...

Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

One of the greatest weaknesses of AI agents that read and understand vast amounts of enterprise data is "hallucination"—the ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Anthropic says AI could soon improve without human intervention Development pause will allow society to deal with AI's implications, startup says Previous attempts to halt AI progress have not been ...

Daniel Liberto is a journalist with over 10 years of experience working with publications such as the Financial Times, The Independent, and Investors Chronicle. The WPA was part of Franklin D.

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Recursion Pharmaceuticals to update on FDA trial design for REC-4881 for FAP in the second half of 2026. Analysts expect potential upside from rare diseases.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...